Brain structure and function as mediators of the effects of amyloid on memory

Neurology

Volumn 84, Issue 11, 2015, Pages 1136-1144

  Mattsson, Niklas ^a,b,c   Insel, Philip S ^a,c   Aisen, Paul S ^d   Jagust, William ^e   Mackin, Scott ^a,f   Weiner, Michael ^a,c  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; FLUORODEOXYGLUCOSE; AMYLOID BETA PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; BRAIN FUNCTION; CLINICAL DEMENTIA RATING; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DAILY LIFE ACTIVITY; EPISODIC MEMORY; FEMALE; FOLLOW UP; GRAY MATTER; HIPPOCAMPUS; HUMAN; IMAGE PROCESSING; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY CONTROL; WECHSLER MEMORY SCALE; BRAIN; METABOLISM; MIDDLE AGED; PHYSIOLOGY; SCINTISCANNING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; BRAIN; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEMORY, EPISODIC; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84925310646     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001375     Document Type: Article

References (40)

1. Knopman DS, Jack CR Jr, Wiste HJ, et al. Brain injury biomarkers are not dependent on β-amyloid in normal elderly. Ann Neurol 2013;73:472-480.
2. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated betaamyloid deposition in elderly subjects. Brain 2009;132: 1310-1323.
3. Han SD, Gruhl J, Beckett L, et al. Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer's disease. Brain Imaging Behav 2012;6:610-620.
4. Landau SM, Mintun MA, Joshi AD, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012;72:578-586.
5. Joshi AD, Pontecorvo MJ, Clark CM, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects. J Nucl Med 2012;53:378-384.
6. Jack CR Jr, Bernstein MA, Fox NC, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 2008;27:685-691.
7. Fischl B, van der Kouwe A, Destrieux C, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex 2004;14:11-22.
8. MacKinnon DP, Fairchild AJ, Fritz MS. Mediation analysis. Annu Rev Psychol 2007;58:593-614.
9. Hayes AF. Beyond Baron and Kenny: statistical mediation analysis in the new millennium. Commun Monogr 2009; 76:408-420.
10. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 2009;66:200-208.
11. Olichney JM, Galasko D, Salmon DP, et al. Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology 1998;51:351-357.
12. Mackin RS, Insel P, Zhang J, et al. Cerebrospinal fluid a-synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's disease. J Alzheimers Dis 2015;43:1007-1016.
13. Fjell AM, McEvoy L, Holland D, Dale AM, Walhovd KB; Alzheimer's Disease Neuroimaging Initiative. Brain changes in older adults at very low risk for Alzheimer's disease. J Neurosci 2013;33:8237-8242.
14. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12:207-216.
15. Villeneuve S, Reed BR, Wirth M, et al. Cortical thickness mediates the effect of β-amyloid on episodic memory. Neurology 2014;82:761-767.
16. Donohue MC, Sperling RA, Salmon DP, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol 2014;71:961-970.
17. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30:572-580.
18. Mungas D, Tractenberg R, Schneider JA, Crane PK, Bennett DA. A 2-process model for neuropathology of Alzheimer's disease. Neurobiol Aging 2014;35:301-308.
19. Josephs KA, Whitwell JL, Knopman DS, et al. Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology 2008;70:1850-1857.
20. Beers SR, Berger RP, Adelson PD. Neurocognitive outcome and serum biomarkers in inflicted versus noninflicted traumatic brain injury in young children. J Neurotrauma 2007;24:97-105.
21. Whitwell JL, Josephs KA. Neuroimaging in frontotemporal lobar degeneration: predicting molecular pathology. Nat Rev Neurol 2012;8:131-142.
22. Mattsson N, Insel PS, Nosheny R, et al. Emerging betaamyloid pathology and accelerated cortical atrophy. JAMA Neurol 2014;71:725-734.
23. Becker JA, Hedden T, Carmasin J, et al. Amyloid-b associated cortical thinning in clinically normal elderly. Ann Neurol 2011;69:1032-1042.
24. Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 2009;65: 176-183.
25. Wirth M, Madison CM, Rabinovici GD, Oh H, Landau SM, Jagust WJ. Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals. J Neurosci 2013;33:5553-5563.
26. Herukka SK, Pennanen C, Soininen H, Pirttilä T. CSF Abeta42, tau and phosphorylated tau correlate with medial temporal lobe atrophy. J Alzheimers Dis 2008;14:51-57.
27. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008;65:1509-1517.
28. Bourgeat P, Chételat G, Villemagne VL, et al. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010;74:121-127.
29. Ossenkoppele R, van der Flier WM, Verfaillie SC, et al. Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. Neurology 2014;82:1768-1775.
30. Oh H, Madison C, Haight TJ, Markley C, Jagust WJ. Effects of age and β-amyloid on cognitive changes in normal elderly people. Neurobiol Aging 2012;33:2746-2755.
31. Rodrigue KM, Kennedy KM, Devous MD Sr, et al. b-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology 2012;78:387-395.
32. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007;130:2837-2844.
33. Hedden T, Oh H, Younger AP, Patel TA. Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology 2013;80:1341-1348.
34. Pike KE, Ellis KA, Villemagne VL, et al. Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study. Neuropsychologia 2011;49:2384-2390.
35. Rentz DM, Locascio JJ, Becker JA, et al. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol 2010;67:353-364.
36. Driscoll I, Resnick SM, Troncoso JC, An Y, O'Brien R, Zonderman AB. Impact of Alzheimer's pathology on cognitive trajectories in nondemented elderly. Ann Neurol 2006;60:688-695.
37. Resnick SM, Sojkova J, Zhou Y, et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 2010;74:807-815.
38. Lim YY, Maruff P, Pietrzak RH, et al. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain 2014;137:221-231.
39. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010;31:1275-1283.
40. Ewers M, Insel P, Jagust WJ, et al. CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb Cortex 2012;22:1993-2004.